These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34861013)

  • 1. Evaluation of Unit Equivalency of Insulin Glargine to Insulin Detemir in an Acute Care Setting.
    Cook EA; Gill T; Taylor S
    J Pharm Technol; 2018 Dec; 34(6):239-243. PubMed ID: 34861013
    [No Abstract]   [Full Text] [Related]  

  • 2. COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
    Galindo RJ; Davis GM; Fayfman M; Reyes-Umpierrez D; Alfa D; Peng L; Tamler R; Pasquel FJ; Umpierrez GE
    Endocr Pract; 2017 Sep; 23(9):1059-1066. PubMed ID: 28683239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring.
    Abe S; Inoue G; Yamada S; Irie J; Nojima H; Tsuyusaki K; Usui K; Atsuda K; Yamanouchi T
    Diabetes Metab Syndr Obes; 2011; 4():283-8. PubMed ID: 21792327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
    Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes.
    Asias BD; Stock EM; Small NL; Getchell KE; Patel JR; Krause JD; Cavness S; Dzenowski CL; Ta M
    J Diabetes Metab Disord; 2015; 14():53. PubMed ID: 26120575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.
    Bilz S; Flückiger M; Meienberg F; Falconnier C; Keller U; Puder JJ
    PLoS One; 2018; 13(8):e0202007. PubMed ID: 30114246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
    Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
    Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
    Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
    Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
    Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol.
    Davis S; Friece C; Roderman N; Newcomer D; Castaneda E
    Pharmacy (Basel); 2017 Apr; 5(2):. PubMed ID: 28970434
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
    Fink H; Herbert C; Gilor C
    Domest Anim Endocrinol; 2018 Jul; 64():17-30. PubMed ID: 29709796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes.
    George J; Giuliano CA; Hartner CL
    J Pharm Pract; 2021 May; ():8971900211017867. PubMed ID: 34002663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.
    Mehta R; Goldenberg R; Katselnik D; Kuritzky L
    Ann Med; 2021 Dec; 53(1):998-1009. PubMed ID: 34165382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.